tbuckley/cabot-search huggingface dataset:
Survey of Src activity and Src-related growth and migration in prostate cancer lines
Authors: Yu-Ming Chang, Lanfang Bai, Joy Yang, Hsing-Jien Kung, Christopher Evans
Journal: Cancer Research (2006)

2505  Prostate cancer (CaP) often develops androgen independence (AI) and proliferates uninhibited despite anti-androgen therapy. Src kinase is a non-receptor tyrosine kinase that mediates a variety of cellular functions. Previous studies have demonstrated that neuropeptide and IL-8 can activate Src kinase and stimulate AI growth in CaP cells. However, a role for Src in prostate cancer is not yet defined. We evaluated Src activation in the most commonly used CaP cell lines and the effect of a Src kinase inhibitor on proliferation and migration. Src activation and basal Src expression levels were profiled in CaP cell lines CWR22Rv1, LNCaP, PC3, DU145, and LAPC-4 in serum-free (SF), charcoal-stripped serum with minimal androgen and small molecules (CS), and regular serum (RS) conditions. CaP cell lines were treated with 62.5nM to 12μM of AZD0530, a novel Src kinase inhibitor in RS and its effects on cell growth were examined. PC3 and DU145 cell migration were assayed in Boyden Chamber in the presence of 5μM AZD0530 with laminin (LMN) and fibronectin (FN) as chemoattractants. Src expression level was found to be about the same in the CaP cell lines examined. In SF media, CWR22Rv1 has the highest relative amount activated Src, followed by DU145 and PC3. Under CS conditions, Src was activated in LNCaP, DU145, and CWR22Rv1. In RS, activated Src was observed in PC3, DU145, and LNCaP. All CaP cells treated with AZD0530 demonstrated dose-dependent inhibition of cell growth in MTT proliferation assays. IC50s for growth in LNCaP, CWR22Rv1, DU145, and PC3 were 3 to 6μM, 6 to 9μM, 3 to 6μM, and 0.5 to 3μM, respectively. Cytostatic or cytostatic growth curves were observed in LNCaP treated with greater than 9μM of AZD0530. Treatment with FN and LMN increased PC3 cell migration to 246 and 225% respectively over basal levels and the addition of AZD0530 to FN and LMN decreased cell migration to 68 and 64% respectively. FN treatment increased cell migration in DU145 to 402% while adding AZD0530 to FN treatment decreased cell migration to 66%. We therefore conclude that Src may be important mediator of cell growth and migration in CaP. Rationale exists for the inhibition of Src in the treatment of androgen-independent CaP.
Prophylactic Foscarnet and Suppression of Pre-Engraftment Immune Reaction Are Essential to Overcome the Development of HHV-6 Encephalitis From the Experience of 496 Adult Cord Blood Transplants in Toranomon Hospital
Authors: Yuki Asano-Mori, Kazuya Ishiwata, Taichi Ikebe, Hikari Ota, Aya Nishida, Masanori Tsuji, Hisashi Yamamoto, Naoyuki Uchida, Koji Izutsu, Akiko Yoneyama, Shigeyoshi Makino, Shuichi Taniguchi
Journal: Blood (2012)
Immunophenotypic Analysis Using CD80 and CD86 Staining Improves the Diagnosis of Waldenstrom's Macroglobulinemia by Evidencing a CD80+/CD86- Profile.
Authors: Andrea Toma, Stephanie Poulain, Aurore Grelier, Magali Le Garff-Tavernier, Frederic Davi, Martine Brissard, Patrick Bonnemye, Stephanie Gueguen, Lucille Musset, Nabih Azar, Pierre Morel, Xavier Leleu, Veronique Leblond, Helene Merle-Beral
Journal: Blood (2009)
The likeness of fetal growth and newborn size across non-isolated populations in the INTERGROWTH-21st Project: the Fetal Growth Longitudinal Study and Newborn Cross-Sectional Study
Authors: José Villar, Aris T. Papageorghiou, Ruyan Pang, Eric O. Ohuma, Leila Cheikh Ismail, Fernando C. Barros, Ann Lambert, Maria Carvalho, Yasmin A. Jaffer, Enrico Bertino, Michael G. Gravett, Doug G. Altman, Manorama Purwar, Ihunnaya O. Frederick, Julia A. Noble, Cesar G. Victora, Zulfiqar A. Bhutta, Stephen H. Kennedy
Journal: The Lancet (2014)
CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study
Authors: Friederike Braulke, Julie Schanz, Katharina S. Götze, Catharina Müller-Thomas, Uwe Platzbecker, Christina Ganster, Klaus Jung, Michael Metz, Sven Detken, Jörg Seraphin, Tim H Brümmendorf, Aristoteles Giagounidis, Ulrich Germing, Kathleen Jentsch-Ullrich, Angelika Böhme, Gesine Bug, Oliver G. Ottmann, Philippe Schafhausen, Michael Stadler, Wolf-Karsten Hofmann, Burkhard Schmidt, Michael Lübbert, Richard F Schlenk, Igor W. Blau, Lorenz Trümper, Detlef Haase
Journal: Blood (2012)
Introduction of Routine Screening for Cerebrovascular Abnormailities in Sickle Cell Disease (SCD) Using Transcranial Doppler Ultrasonography (TCD).
Authors: David C. Rees, Susan E. Height, Moira C. Dick, Swee Lay Thein, Josef Jarosz, Keith Pohl, Mark Young, David Goss, Colin Deane
Journal: Blood (2005)
Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib.
Authors: Oliver Hantschel, Uwe Rix, Tilmann Buerckstuemmer, Uwe Schmidt, Michael Kneidinger, Keiryn L. Bennett, Ines Kaupe, Wilfried Ellmeier, Peter Valent, Giulio Superti-Furga
Journal: Blood (2007)
Financial Conflicts of Interest Among Hematologist-Oncologists on Twitter
Authors: Derrick L. Tao, Aaron Boothby, Joel McLouth, Vinay Prasad
Journal: JAMA Internal Medicine (2017)

Dora H. Lin, MHS; Eleanor Lucas, BA; Irene B. Murimi, PhD; Andrew Kolodny, MD; G. Caleb Alexander, MD, MS
Hb Barts’s Quantitation in Neonatal Cord Blood Screening Samples
Authors: Salam Alkindi, Anil Pathare, Shoaib AlZadjali, Ali AlMadhani, Hamood AlHaddabi, Shanmugaonkar Muralitharan, David Gravell, J. David Dennison, Rajagopal Krishnamoorthy
Journal: Blood (2008)
Universal health coverage, priority setting, and the human right to health
Authors: Benedict Rumbold, Rachel Baker, Octavio Ferraz, Sarah Hawkes, Carleigh Krubiner, Peter Littlejohns, Ole F Norheim, Thomas Pegram, Annette Rid, Sridhar Venkatapuram, Alex Voorhoeve, Daniel Wang, Albert Weale, James Wilson, Alicia Ely Yamin, Paul Hunt
Journal: The Lancet (2017)
Possible inducible skin-associated lymphoid tissue (iSALT)-like structures with CXCL13<sup>+</sup>fibroblast-like cells in secondary syphilis
Authors: T. Kogame, T. Nomura, T. Kataoka, M. Hirata, C. Ueshima, M. Matsui, K. Kabashima
Journal: British Journal of Dermatology (2017)
PTEN as prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck.
Authors: M. P. Snietura, M. Jaworska, J. Mlynarczyk-Liszka, W. Piglowski, G. Wozniak, D. Lange, R. Suwinski
Journal: Journal of Clinical Oncology (2010)

5519 Background: The tumor suppressor PTEN is known to control a variety of processes related to cell proliferation, survival and growth. In this study we analyzed the influence of PTEN expression on the outcome of randomized clinical trial of conventional (CF) versus 7-days-a-week postoperative radiotherapy (p-CAIR) for squamous cell cancer of the head and neck. Methods: The patients with cancer of the oral cavity, oropharynx and larynx were randomized to receive 63 Gy in fractions of 1.8 Gy given 5-days-a-week or 7-days-a-week (Suwinski et al. Radiother Oncol. 2008;87:155-163). Out of 279 patients enrolled to the study 147 paraffin blocks were available for immunohistochemical assesment of PTEN (73 CF, 74 p-CAIR) To evaluate the effect of fractionation relative to PTEN expression the data on loco-regional tumor control (LRC) were analyzed using Kaplan-Meier method and compared using Cox f- test. The prognostic value of PTEN was tested using multivariate Cox model. Results: Tumors with high intensity of PTEN staining had significant gain in LRC from p-CAIR (5 year LRC 93% vs 69%, for p=CAIR vs. CF, p=0.01, RR=0.25). By contrast, tumors with low intensity of PTEN did not gain from p-CAIR (5 year LRC 56% vs 47%, p=0.49, RR=0.94). Intensity of PTEN highly affected LRC in a whole group of 147 patients (5 year LRC 80% vs. 52% for high vs. low PTEN, p=0.0008, RR=0.32). We have previously analyzed the prognostic and predictive potential of the other variables and markers in the same group of patients, including neck node involvement, EGFR, nm23, Ki-67, p-53, cyclin D1, tumor site and margins (Suwinski et al. Int J Radiat Oncol Biol Phys. 2009 Sep 2, Epub). A multivariate Cox analysis now indicates that the prognostic potential of PTEN exceeds that of the other variables that significantly and independently affect LRC (RR is 2.8, 2.0, 1.9 and 1.9 for PTEN, neck node involvment, EGFR and nm23 expression respectively, p=00004). Conclusions: These results suggest that PTEN may serve as a prognostic and predictive marker in postoperative radiotherapy for high-risk squamous cell cancer of the head and neck. No significant financial relationships to disclose.
High affinity anti IL-6 antibodies for the treatment of prostate cancer
Authors: A. A. Epenetos, M. Deonarain, M. Wright
Journal: Journal of Clinical Oncology (2005)

4803 Interleukin (IL-6) is a pleiotropic cytokine that has been implicated in a variety of cancers. It has been shown that IL-6 is a survival factor and is involved in the promotion of prostate cancer and also contributes to chemotherapy resistance. This has led to treatments based on the systemic depletion of IL-6 using monoclonal antibodies (MAb). The affinity of a MAb directly affects the neutralisation potency, which suggests that this approach could be improved using very high affinity antibodies. We have developed a method to make recombinant antibodies which can attain affinities 10–1000 fold higher than conventional antibodies, by exploiting the ‘chelate’ effect. We have selected single chain Fv antibodies (scFvs) which bind to two non-overlapping epitopes of the IL-6, linked by an optimally selected peptide. These antibodies have been characterised and found to be super-high affinity chelating scFvs, and capable of depleting IL-6 from the environment of prostate cancer. Such molecules could rapidly be developed into prostate cancer therapeutics. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Somantis Somantis
Bispecific SCORPION™ Molecules Effectively Redirect T-Cell Cytotoxicity Toward CD19-Expressing Tumor Cells
Authors: Ruth A. Chenault, Rebecca Gottschalk, Gabriela Hernandez-Hoyos, Jennifer Wiens, Brian Gordon, Jennifer Klee, Jessica Bienvenue, Maria Dasovich, John Kumer, Megan Aguilar, Jeannette Bannink, Catherine J. McMahan, Sateesh Natarajan, Paul A. Algate, John W. Blankenship
Journal: Blood (2012)
The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review
Authors: Nicola Fossati, Peter-Paul M. Willemse, Thomas Van den Broeck, Roderick C.N. van den Bergh, Cathy Yuhong Yuan, Erik Briers, Joaquim Bellmunt, Michel Bolla, Philip Cornford, Maria De Santis, Ekelechi MacPepple, Ann M. Henry, Malcolm D. Mason, Vsevolod B. Matveev, Henk G. van der Poel, Theo H. van der Kwast, Olivier Rouvière, Ivo G. Schoots, Thomas Wiegel, Thomas B. Lam, Nicolas Mottet, Steven Joniau
Journal: European Urology (2017)
A phase II study of capecitabine and weekly docetaxel combination chemotherapy in patients with metastatic breast cancer
Authors: F. Puglisi, S. Scalone, A. M. Minisini, M. Mansutti, D. Crivellari, A. Buonadonna, M. Zanetti, P. Ermacora, A. Piga, A. Veronesi
Journal: Journal of Clinical Oncology (2005)

804 Background: Preclinical and clinical data support a synergistic interaction between capecitabine and docetaxel. This effect is thought to be mediated through docetaxel upregulation of thymidine phosphorylase (TP). Previous studies have demonstrated that, after single-dose administration of a taxane, TP reaches a peak on days 6 to 8. We aimed at exploring the impact of capecitabine administration at time of the hypothesized docetaxel-induced TP peak on the activity of this combination. Methods: Eligible patients (pts) had histologically-proved metastatic breast cancer (MBC), no more than one chemotherapy line for MBC, previous anthracycline treatment or anthracycline contraindication, and measurable disease. Treatment schedule: docetaxel 35 mg/m2 i.v. days 1, 8, 15 and oral capecitabine 625 mg/m2 twice daily days 8–21. Cycles were repeated every 28 days until progression or unacceptable toxicity. Results: From July 2002 to November 2004, 32 pts were enrolled. Median age was 58 years (range 34–74). Median number of metastatic sites was 2 (range 1–5). The 28 pts evaluable for response and toxicity received a total of 135 cycles of chemotherapy (10 pts are still on treatment). Nineteen pts had no previous chemotherapy for MBC. Two pts had a complete response, 16 a partial response, 6 stable disease, while 4 progressed. The overall response rate was 64% (95% CI, 55–73%), median progression free survival was 6 months. Grade 3/4 bone marrow toxicity was reported in 4 pts, but no febrile neutropenia occurred. Non-hematological grade >1 adverse events included mucositis in 9 pts, diarrhea in 7, nail changes in 10, hand-foot syndrome in 7, asthenia in 4. At a median follow-up of 6 months, 22 pts are alive. Quality of life evaluation is pending. Conclusions: This regimen proved to be active and devoid of life-threatening toxicity. The activity resulting from this schedule is in line with the hypothesis of enzymatic-based synergistic interaction between docetaxel and capecitabine. No significant financial relationships to disclose.
Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy
Authors: E. Auclin, A. Zaanan, D. Vernerey, R. Douard, C. Gallois, P. Laurent-Puig, F. Bonnetain, J. Taieb
Journal: Annals of Oncology (2017)

Since the MOSAIC study, oxaliplatin-based adjuvant chemotherapy has been the standard treatment of stage III colon cancer. Combination therapy with fluoropyrimidines and oxaliplatin has improved overall survival (OS) and reduced the risk of recurrence in patients with resected stage III colon cancer. However, only 20% of patients really benefit from adjuvant chemotherapy, exposing 80% of patients to unnecessary toxicity. Recent analyses of large multicenter adjuvant studies have focused on the prognostication of OS and disease-free survival in stage III colon cancer in order to reduce over-treatment and to find more accurate prognostic tools than those used for adjuvant treatment decision-making in stage II disease. Indeed, clinical and pathological prognostic factors, although important, are not sufficient to decide which stage III patients will benefit from adjuvant therapy, and biomarkers will help select patient that need adjuvant treatment. Molecular markers such as microsatellite status and BRAF and KRAS mutations have recently been explored, and molecular signatures have been identified as promising prognostic factor for OS. Furthermore, recent studies have highlighted the prognostic value of immune infiltration. This review focuses on pathologic, immunologic and molecular prognostic markers for stage III colon cancer that could help clinicians tailor adjuvant treatment in a comprehensive transversal approach.
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Authors: Al B. Benson, Alan P. Venook, Lynette Cederquist, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Peter C. Enzinger, Alessandro Fichera, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Christina S. Wu, Kristina M. Gregory, Deborah Freedman-Cass
Journal: Journal of the National Comprehensive Cancer Network (2017)

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.
CDC Says More Needle Exchange Programs Needed to Prevent HIV
Authors: Jennifer Abbasi
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Are miRNAs Appropriate Biomarkers for Radiologic Measures of Tissue Injury in Multiple Sclerosis?
Authors: Darin T. Okuda
Journal: JAMA Neurology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada
Authors: Ganesh Raghu
Journal: European Respiratory Journal (2017)

Idiopathic pulmonary fibrosis (IPF) is a very complex disease and despite the diagnostic criteria published in evidence-based guidelines in 2011, there are significant pitfalls in making an accurate diagnosis of IPF [1]. This has surfaced as a reason for the high rate of screen failures in recent prospective clinical trials for IPF [2–5]. Since epidemiological studies are simply based on data entered in medical records and health claim databases, and are not subject to validation by review of actual raw data by experienced experts and multidisciplinary discussions among experts in the field of interstitial lung disease, the reports of the incidence and prevalence of IPF can only be estimates of diagnosis made on assumptions and, thus, must be interpreted with caution. Indeed, tracking the true occurrence of IPF is challenging [6]. We must be mindful of the caveats of the methods used to estimate the incidence and prevalence of IPF <http://ow.ly/MAa0306XRLp>
Comprehensive Protein Expression Analysis of Chronic Lymphocytic Leukemia Uncovers a Correlation of CDK4, P27 and P53 with Hierarchical Risk and Suggests a Dichotomy of Apoptosis and Proliferation.
Authors: Dirk Winkler, Christof Schneider, Daniela Nitsch, Kerstin Schulze, Thorsten Zenz, Julia Mohr, Andreas Buehler, Annett Habermann, Manuela Zucknick, Axel Benner, Hartmut Döhner, Stephan Stilgenbauer, Daniel Mertens
Journal: Blood (2009)
Lin28B Increases Fetal Hemoglobin and Regulates BCL11A Expression in Human Erythroid Tissues
Authors: Jaira F. de Vasconcellos, Y. Terry Lee, Joan Yuan, Colleen Byrnes, Seung-Jae Noh, Emily R. Meier, Ki Soon Kim, Antoinette Rabel, Stefan A. Muljo, Jeffery L. Miller
Journal: Blood (2012)
Regulation of Chronic Myelogenous Leukemia Stem Cells by Leukemia Oncogene Evi1
Authors: Tomohiko Sato, Susumu Goyama, Keisuke Kataoka, Takako Tsuruta, Masahiro Nakagawa, Keiki Kumano, Katsuyoshi Kumagai, Naoto Kubota, Takashi Kadowaki, Mineo Kurokawa
Journal: Blood (2011)
Outcome of Patients with T-Cell ALL Post Frontline Therapy Failure
Authors: Christine Parseghian, Hagop M Kantarjian, Jorge E. Cortes, Guillermo Garcia-Manero, Marina Konopleva, William Wierda, Tapan Kadia, Srdan Verstovsek, Koji Sasaki, Farhad Ravandi, Koichi Takahashi, Nitin Jain, Sherry Pierce, Elias Jabbour
Journal: Blood (2015)
Impact of renal impairment and granulocyte colony stimulating factor (GCSF) on bleomycin-induced pneumonitis (bleo lung), febrile neutropenia (FN), and survival in patients (pts) with germ cell tumor (GCT) treated with chemotherapy (chemo).
Authors: Ben Tran, Malcolm J. Moore, Eitan Amir, Michael A Jewett, Lynn Anson-Cartwright, Jeremy F. G. Sturgeon, Peter W. M. Chung, Padraig Richard Warde, Philippe Bedard
Journal: Journal of Clinical Oncology (2012)

328 Background: Use of GCSF and the development of renal impairment in GCT pts receiving chemo are common, but their effect on toxicity and survival is unclear. This study examines the impact of GCSF and renal impairment on bleo lung, FN and survival, in GCT pts receiving 1st line chemo. Methods: Clinical data from our institutional GCT database was complemented by review of radiology, pharmacy and medical records. All GCT pts receiving 1st line chemo between 1-Jan-00 and 31-Dec-10 were included. Pts receiving at least one GCSF dose were identified. Renal impairment during chemo was defined as any serum creatinine above the institutional upper limit of normal. Bleo lung was graded (G1-5) using CTCAE criteria. FN was defined as temperature ≥38C and neutrophil count &lt;1.0. Results: The cohort consisted of 260 GCT pts, median age 31.5 years, 171 (66%) had IGCCCG good risk disease, 42 (16%) intermediate, and 41 (16%) poor, while 6 (2%) received adjuvant chemo. 159 (61%) received GCSF and 49 (19%) developed renal impairment. 212 (82%) received BEP of which 73 (34%) developed bleo lung (56 pts G1 asymptomatic, 13 pts G2, 4 pts ≥G3). Renal impairment was associated with bleo lung in univariate (OR 2.87, p=0.008) and multivariate (OR 2.69, p=0.01) analyses. GCSF was associated with increasing severity of bleo lung (OR 1.86, p=0.045) but this was not significant in a multivariate analysis (OR 1.72, p=0.08). FN occurred in 33 (13%) of 260 pts. Renal impairment (OR 3.91, p=0.001) was associated with FN. Primary GCSF prophylaxis reduced FN (OR 0.26, p=0.001), however, 8 (7%) of 112 patients developed FN in spite of GCSF prophylaxis. Survival analyses demonstrated GCSF and renal impairment did not impact progression free or overall survival (OS), however, bleo lung was associated with poorer OS in a multivariable Cox proportional hazards analysis (HR 2.85, p=0.029). Conclusions: Our findings demonstrate both renal impairment and GCSF are risk factors for bleo lung, while renal impairment itself is also a risk factor for FN. Additionally, we identify bleo lung as a significant poor prognostic factor for OS.